Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

This was the stock's second consecutive day of gains.